Immediate Impact
15 standout
Citing Papers
AXL signaling in cancer: from molecular insights to targeted therapies
2025 Standout
Properties of FDA-approved small molecule protein kinase inhibitors: A 2024 update
2024 Standout
Works of Colette Owens being referenced
Nivolumab plus cabozantinib in patients with non-clear cell renal cell carcinoma: Results of a phase 2 trial.
2021
Initial results of a multicenter, investigator initiated study of MRD driven time limited therapy with zanubrutinib, obinutuzumab, and venetoclax.
2020
Author Peers
| Author | Last Decade | Papers | Cites | |||||
|---|---|---|---|---|---|---|---|---|
| Colette Owens | 68 | 94 | 34 | 142 | 106 | 20 | 218 | |
| Lukas Delasos | 42 | 120 | 15 | 154 | 63 | 20 | 223 | |
| Jacquelyn Reuther | 61 | 72 | 20 | 78 | 86 | 16 | 251 | |
| Morana Vojnic | 40 | 128 | 19 | 159 | 124 | 23 | 264 | |
| Umair Majeed | 33 | 141 | 13 | 151 | 89 | 26 | 274 | |
| Murtuza Rampurwala | 40 | 159 | 11 | 69 | 83 | 27 | 260 | |
| Luis Gros | 33 | 87 | 53 | 64 | 80 | 15 | 238 | |
| Audrey Monneur | 49 | 138 | 15 | 75 | 57 | 20 | 244 | |
| Daniela Boggiani | 59 | 194 | 17 | 121 | 80 | 15 | 275 | |
| Brian L. Burnette | 28 | 144 | 31 | 119 | 71 | 25 | 255 | |
| Chunrong Zhu | 60 | 152 | 11 | 136 | 111 | 16 | 286 |
All Works
Loading papers...